Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congress

Eloxx Pharmaceuticals, a leader in ribosomal RNA-targeted genetic therapies for rare diseases, has highlighted recent Alport syndrome natural history data presented at the 60th ERA (European Renal Association) Congress. The RaDaR natural history study indicates that patients with autosomal recessive COL4A4 mutations have the severest form of the disease, with a more rapid progression to kidney f..